Celularity(us:CELU)
2.33
+4.95%
Updated on 2024-12-22
Open:2.18
Close:2.33
High:2.50
Low:2.16
Pre Close:2.22
Volume:131637.00
Amount:307044.75
Turnover:0.59%
Shares:22.48M
MarketCap:52.39M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 31 | 944811 | 4.31% | 0 | 7 | 12 |
| 2024-03-31 | 42 | 833363 | 3.83% | 5 | 8 | 19 |
| 2023-12-31 | 46 | 827716 | 0.43% | 2 | 6 | 23 |
| 2023-09-30 | 60 | 15689209 | 8.10% | 5 | 13 | 23 |
| 2023-06-30 | 72 | 35350263 | 19.55% | 14 | 7 | 38 |
| 2023-03-31 | 79 | 34238109 | 20.75% | 7 | 19 | 36 |
| 2022-12-31 | 89 | 34303670 | 23.04% | 19 | 25 | 32 |
| 2022-09-30 | 80 | 35075111 | 24.27% | 15 | 33 | 20 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 384918 | 1.77% | 11597 | 3.11% |
| 2024-03-31 | Geode Capital Management, Llc | 134643 | 0.62% | 36832 | 37.66% |
| 2024-03-31 | Blackrock Inc. | 76359 | 0.35% | -782 | -1.01% |
| 2024-03-31 | Cresset Asset Management, Llc | 35000 | 0.16% | 35000 | |
| 2024-03-31 | Renaissance Technologies Llc | 29768 | 0.14% | -54579 | -64.71% |
| 2024-03-31 | Northern Trust Corp | 27345 | 0.13% | 13520 | 97.79% |
| 2024-03-31 | State Street Corp | 24930 | 0.11% | 0 | |
| 2024-03-31 | Hb Wealth Management, Llc | 24000 | 0.11% | 18000 | 300.00% |
| 2024-03-31 | Royal Bank Of Canada | 22500 | 0.10% | 0 | |
| 2024-03-31 | Ipg Investment Advisors Llc | 17169 | 0.08% | -1 | -0.01% |
About
Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.
Address:170 Park Avenue
Website:http://celularity.com
Market Movers